Study on the Application of Percutaneous Coronary Intervention in Patients with Chronic Coronary Syndrome Combined with Renal Disease

© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Objective: To analyze the clinical effect of percutaneous coronary intervention in the treatment of chronic coronary syndrome combined with kidney disease. Methods: 150 patients with chronic coronary syndrome combined with renal disease admitted to a hospital from June 2023 to May 2024 were selected, and were divided into the control group and the observation group, 75 cases each, using the mean score method. The control group implemented conventional drug (clopidogrel, aspirin, statins) treatment, and the observation group implemented percutaneous coronary intervention on this basis, comparing the two groups’ treatment effects. Results: The mortality rate (9.33%) and the deterioration rate of renal function (5.33%) of patients in the observation group during the treatment period were significantly lower than those of the control group (21.33%) and (16.00%). The average hospitalization time of patients in the observation group was shorter than that of the control group (15.75 ± 4.24) days. The recurrence rate of angina pectoris of the patients of the observation group in the three months after discharge from the hospital was lower than that of the control group (25.33%) and that of the observation group was lower than that of the control group (6.67%), the difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the levels of LVEDD, LVESD, and LVEF between the two groups (P > 0.05). After three months of treatment, the LVEDD (52.55 ± 4.02) mm and LVESD (41.44 ± 2.17) mm in the patients of the observation group were lower than those of the control group (57.37 ± 3.74) mm and (46.44 ± 2.59) mm; LVEF (50.78 ± 5.97)% of patients in the observation group was higher than that of (43.06 ± 5.92)% in the control group, and the difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the levels of CK-MB and cTnI between the two groups (P > 0.05). At 24h and 72h after treatment, the levels of CK-MB and cTnI in patients of the observation group and the control group were (35.21 ± 9.81) U/L, (1.24 ± 0.34) μg/L, (13.19 ± 5.12) U/L, (0.36 ± 0.08) μg/L and (38.79 ± 10.84) U/L, (1.45 ± 0.32) μg/L, (19.87 ± 4.76) μg/L, (0.58 ± 0.11) μg/L, the difference was statistically significant (P < 0.05). Conclusion: Percutaneous coronary intervention is effective in treating chronic coronary syndrome combined with renal disease, which can significantly improve the level of a patient’s cardiac function and reduce the level of CK-MB and cTnI, and is worth being widely used in clinical practice.

References

Zhou L, Li Q, Lin J, et al., 2024, Clinical Study of Thromboelastography Combined with CYP2C19 Assay to Guide Postoperative Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Chinese Contemporary Medicine, 31(21): 55–58.

Zhang QX, Zhu JB, Jing ZP, et al., 2024, No-Reflow Phenomenon and Related Factors During Percutaneous Coronary Intervention in Elderly Patients with Acute Coronary Syndrome. Chinese Journal of Geriatric Multiorgan Diseases, 23(7): 500–504.

Xu Lan, (2023), Observation on the Effect of Percutaneous Coronary Intervention Combined with Tongxinluo in the Treatment of Acute Coronary Syndrome. Heilongjiang Traditional Chinese Medicine, 52(5): 24–26.

Xu Y, Liu Y, Huang D, et al., 2023, Clinical Study on the Treatment of Postoperative Upper Gastrointestinal Bleeding After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome by Yiqi Hemostatic Formula. Beijing Traditional Chinese Medicine, 42(5): 508–512.

Wang Y, Li X, Zhu X, et al., 2023, Comparative Observation of Different Types of Clopidogrel for the Treatment of Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of Community Medicine, 21(8): 405–410.

Fan X, Li C, Mu L, et al., 2022, Predictive Value of Serum Adropin Levels in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes on the Extent of Coronary Artery Disease and Slow Blood Flow During Percutaneous Coronary Intervention. Journal of Clinical Emergency Medicine, 23(5): 310–315.

Wang T, Zhao LS, Zhang L, et al., 2021, Effect of Hemoglobin Concentration on the Prognosis of Patients After Percutaneous Coronary Intervention for Chronic Coronary Syndrome. China Cardiovascular Disease Research, 19(9): 829–834.

Zhang Q, 2021, Analysis of the Role of Percutaneous Coronary Intervention in the Prevention of Complications in the Treatment of Acute Coronary Syndrome. China Continuing Medical Education, 13(24): 136–139.

Ling HX, Qin W, Zhu L, et al., 2021, Construction of Comprehensive Evaluation Index for Percutaneous Coronary Intervention for Acute Coronary Syndrome. Chinese Clinical Medicine, 28(3): 449–454.

Yu Z, Zhang G, Yang F, et al., 2021, Analysis of the Effectiveness and Safety of Percutaneous Coronary Intervention for the Treatment of Patients with Acute Coronary Syndrome Combined with Regular Dialysis. Journal of Clinical Military Medicine, 49(1): 52–54.

Previous article in this issue

Next article in this issue